Suppression of epithelial ovarian cancer invasion into the omentum by 1α,25-dihydroxyvitamin D3 and its receptor

Lungchukiet, Panida; Sun, Yinyan; Kasiappan, Ravi; Quarni, Waise; Nicosia, Santo V.; Zhang, Xiaohong; Bai, Wenlong

doi:10.1016/j.jsbmb.2014.11.005

Cited by 31 publications

(25 citation statements)

References 41 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…At 14 days after i.p. injection, tumor infiltration first appeared in the omentum, which is a tissue attached to the greater curvature of the stomach and is the most common site for EOC metastatic spread [35] . As the disease progressed, a greater extent of the omentum was invaded by cancer cells (Fig.…”

Section: Characterization Of the Intraperitoneal Injection Ovarian Camentioning

confidence: 99%

“…This indicated that the urine proteins could show a significant immune response on the 14th day after the injection of tumor cells. In 80% of EOC patients, the cancer has usually spread to the omentum by the time of diagnosis [35] . In the pathology findings of our study, the omentum was first invaded by on day 14 in the model.…”

Section: Nutu-19 Cellsmentioning

confidence: 99%

“…In the pathology findings of our study, the omentum was first invaded by on day 14 in the model. The omentum is a lymphoid organ controlling the peritoneal cavity immune response; omental adipocytes promote EOC metastasis by providing energy for rapid tumor growth [35,72] . The pathology changes in ovarian cancer corresponded to the changes in urinary proteins, which suggests that urine could sensitively reflect the immune response process of cancer.…”

Section: Nutu-19 Cellsmentioning

confidence: 99%

See 2 more Smart Citations

Dynamic changes in the urine proteome in two ovarian cancer rat models

Zhang

Meng

et al. 2019

Preprint

View full text Add to dashboard Cite

Ovarian cancer is the most lethal gynecological malignancy in women, and it is likely to metastasize and has a poor prognosis. The early and reliable diagnosis and monitoring of ovarian cancer is very important. Without a homeostasis mechanism, urine can reflect early systemic changes in the body and has a great potential to be used for the early detection of cancer. This study tested whether early changes could be detected in two ovarian cancer rat models. Two rat models were established by either intraperitoneal (i.p.) or orthotopic (o.t.) injection of NuTu-19 ovarian cancer cells in female Fischer344 rats. Urine samples from ovarian cancer rats were collected at five time points during cancer development, and urinary proteins from the rats were profiled by liquid chromatography coupled with tandem mass spectrometry (LC-MS/MS). Compared with pre-injection samples, 49 differential proteins that have human orthologues were significantly changed in the orthotopically injected model. Among them, 24 of the differential proteins have previously been reported to be associated with ovarian cancer, six of which were reported to be biomarkers of ovarian cancer. On the 7th day after orthotopic injection, four differential proteins (APOA1, OX2G, CHMP5, HEXB) were identified before obvious metastases appeared. In the intraperitoneal injection model, 76 differential proteins were changed during the course of ovarian cancer development. The results show that urine proteins could enable the early detection and monitoring of ovarian cancer progression and could lay a foundation for further exploration of the biomarkers of ovarian cancer. IntroductionOvarian cancer (OC) is the most lethal gynecological malignancy and it is the fifth leading cause of cancer death in women [1] , mainly because OC can spread to intraperitoneal tissues, such as the omentum in the peritoneal cavity, by the time of diagnosis [2] . The strongest risk factors for this disease are an advanced age and a family history of ovarian cancer. Epithelial ovarian cancer (EOC) is the most common ovarian malignancy and comprises 90% of all ovarian cancers [3] . More than 75% of affected women ovarian carcinomas are not diagnosed until a late stage (stage III or IV) because early-stage disease is not obvious and early symptoms, as well as symptoms of late-stage disease, are nonspecific.Pelvic or abdominal pain, a feeling of pelvic mass and abdominal swelling are the main clinical symptoms, but these are not specific to OC [4] . Currently, women who have symptoms consistent with ovarian cancer usually undergo a physical examination, transvaginal ultrasonography, and measurement of biomarkers such as CA125, but imaging and serum biomarkers tests are of limited 2 value in the early diagnosis of the ovarian carcinomas [5] . The treatment of ovarian cancer usually involves surgery and intraperitoneal and intravenous chemotherapy [6] . At present, patients are typically diagnosed at the advanced stage when the cancer has disseminated within the peritoneal cavity, and comp...

show abstract

Section: Characterization Of the Intraperitoneal Injection Ovarian Camentioning

confidence: 99%

Section: Nutu-19 Cellsmentioning

confidence: 99%

Section: Nutu-19 Cellsmentioning

confidence: 99%

See 1 more Smart Citation

Dynamic changes in the urine proteome in two ovarian cancer rat models

Zhang

Meng

et al. 2019

Preprint

View full text Add to dashboard Cite

show abstract

“…Omentum was one of the organs most commonly involved in SOI metastasis, while omentum metastasis was rarely observed in COI. As it is understood that the omentum is the main target organ of ovarian cancer metastasis, up to 80% of epithelial ovarian cancer patients are found to have omentum metastasis when diagnosed (34,35). This suggests that the biological characteristics of cancer cells in the SOI model are more closely related to clinical disease, thus SOI is more clinically relevant.…”

Section: Organs -----------------------------------------------------mentioning

confidence: 99%

Establishment of two ovarian cancer orthotopic xenograft mouse models for in vivo imaging: A comparative study

Guo

Cai

Zhang

et al. 2017

International Journal of Oncology

View full text Add to dashboard Cite

Orthotopic tumor animal models are optimal for preclinical research of novel therapeutic interventions. The aim of the present study was to compare two types of ovarian cancer orthotopic xenograft (OCOX) mouse models, i.e. cellular orthotopic injection (COI) and surgical orthotopic implantation (SOI), regarding xenograft formation rate, in vivo imaging, tumor growth and metastasis, and tumor microenvironment. The tumor formation and progression were monitored by bioluminescent in vivo imaging. Cell proliferation and migration abilities were detected by EdU and scratch assays, respectively. Expression of α-SMA, CD34, MMP2, MMP9, vimentin, E-cadherin and Ki67 in tumor samples were detected by immunohistochemistry. As a result, we successfully established COI- and SOI-OCOX mouse models using ovarian cancer cell lines ES2 and SKOV3. The tumor formation rate in the COI and SOI models were 87.5 and 100%, respectively. Suspected tumor cell leakage occurred in 37.5% of the COI models. The SOI xenografts grew faster, held larger primary tumors, and were more metastatic than the COI xenografts. The migration and proliferation properties of the cells that generated SOI xenografts were significantly starker than those deriving COI xenografts in vitro. The tumor cells in SOI xenografts exhibited a mesenchymal phenotype and proliferated more actively than those in the COI xenografts. Additionally, compared with the COI tumors, the SOI tumors contained more cancer associated fibroblasts, matrix metallopeptidase 2 and 9. In conclusion, SOI is a feasible and reliable technique to establish OCOX mouse models mimicking the clinical process of ovarian cancer growth and metastasis, although SOI is more technically difficult and time-consuming than COI.

show abstract

“…Further analyses have demonstrated that 1,25D3 induces microRNA target genes to decrease telomerase expression for cell death induction [10, 11] and to inhibit leptin and estrogen-induced tumor growth [12], suggesting that 1,25D3 has an important role in cutting down obesity-associated cancer risks in women [13]. More recent studies have shown that ovarian cancer invasion is suppressed by 1,25D3 through the cooperative actions of epithelial and stromal VDR [14]. Overall, these studies project VDR as a new therapeutic target for ovarian cancer intervention.…”

Section: Introductionmentioning

confidence: 99%

RIPK1 binds to vitamin D receptor and decreases vitamin D-induced growth suppression

Quarni

Lungchukiet

Tse

et al. 2017

The Journal of Steroid Biochemistry and Molecular Biology

Self Cite

View full text Add to dashboard Cite

Receptor interacting protein kinase 1 (RIPK1) is an enzyme acting downstream of tumor necrosis factor alpha to control cell survival and death. RIPK1 expression has been reported to cause drug resistance in cancer cells, but so far, no published studies have investigated the role of RIPK1 in vitamin D signaling. In the present study, we investigated whether RIPK1 plays any roles in 1,25-dihydroxyvitamin D3 (1,25D3)-induced growth suppression. In our studies, RIPK1 decreased the transcriptional activity of vitamin D receptor (VDR) in luciferase reporter assays independent of its kinase activity, suggesting a negative role of RIPK1 in 1,25D3 action. RIPK1 also formed a complex with VDR, and deletion analyses mapped the RIPK1 binding region to the C-terminal ligand-binding domain of the VDR. Subcellular fractionation analyses indicated that RIPK1 increased VDR retention in the cytoplasm, which may account for its inhibition of VDR transcriptional activity. Consistent with the reporter analyses, 1,25D3-induced growth suppression was more pronounced in RIPK1-null MEFs and RIPK1-knockdown ovarian cancer cells than in control cells. Our studies have defined RIPK1 as a VDR repressor, projecting RIPK1 depletion as a potential strategy to increase the potency of 1,25D3 and its analogs for cancer intervention.

show abstract

Suppression of epithelial ovarian cancer invasion into the omentum by 1α,25-dihydroxyvitamin D3 and its receptor

Cited by 31 publications

References 41 publications

Dynamic changes in the urine proteome in two ovarian cancer rat models

Dynamic changes in the urine proteome in two ovarian cancer rat models

Establishment of two ovarian cancer orthotopic xenograft mouse models for in vivo imaging: A comparative study

RIPK1 binds to vitamin D receptor and decreases vitamin D-induced growth suppression

Contact Info

Product

Resources

About